Statins, diabetes, obesity, nonalcoholic fatty liver disease, and hepatocellular carcinoma

被引：0

作者：

Jun Han ^{[1
]}

WenTao Yan ^{[1
,2
]}

Bing Quan ^{[1
,2
]}

MingDa Wang ^{[1
]}

Tian Yang ^{[1
]}

机构：

[1] Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, the Second Military Medical University

[2] Department of Clinical Medicine, the Second Military Medical University

来源：

Hepatobiliary & Pancreatic Diseases International | 2019年 / 18卷 / 02期

关键词：

HCC; Statins; and hepatocellular carcinoma; diabetes; nonalcoholic fatty liver disease; obesity;

D O I：

暂无

中图分类号：

R735.7 [肝肿瘤]; R587.1 [糖尿病]; R575 [肝及胆疾病];

学科分类号：

100214 ; 1002 ; 100201 ;

摘要：

<正>To the Editor:We read with great interest the recent article by Chang et al.[1].By analyzing the data of 1350 cirrhotic patients,the authors concluded that statin significantly decreases the risk of decompensation of cirrhosis,mortality and hepatocellular carcinoma

引用

页码：202 / 202

页数：1

共 3 条

[1]

Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, and Hepatocellular Carcinoma[J] . Mazen Noureddin,Mary E. Rinella.Clinics in Liver Disease . 2015 (2)

[2]

Diabetes mellitus and decompensated cirrhosis: Risk of hepatic encephalopathy in different age groups (糖尿病与失代偿性肝硬化：不同年龄组的肝性脑病风险)[J] . Zeeshan Butt,Nauman A. Jadoon,Osman N. Salaria,Kamran Mushtaq,Irbaz B. Riaz,Ahmed Shahzad,Ali M. Hashmi,Shahid Sarwar.Journal of Diabetes . 2013 (4)

[3]

Systematic review: the association between obesity and hepatocellular carcinoma – epidemiological evidence[J] . D.SAUNDERS,D.SEIDEL,M.ALLISON,G.LYRATZOPOULOS.Alimentary Pharmacology & Therapeutics . 2010 (10)

← 1 →